Acuta Capital Partners’s Cymabay Therapeutics CBAY Stock Holding History

Acuta Capital Partners’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-492,155	Closed	-$11.6M	–	44
2023 Q4	$11.6M	Buy	492,155 +74,155	+18%	+$1.32M	6.54%	2
2023 Q3	$6.23M	Sell	418,000 -12,000	-3%	-$159K	4.18%	11
2023 Q2	$4.71M	Sell	430,000 -448,500	-51%	-$4.18M	3.19%	14
2023 Q1	$7.66M	Sell	878,500 -136,500	-13%	-$1.09M	5.64%	4
2022 Q4	$6.36M	Buy	+1,015,000	New	+$3.86M	3.92%	11
2021 Q4	–	Sell	-301,904	Closed	-$1.1M	–	55
2021 Q3	$1.1M	Hold	301,904	–	–	0.39%	42
2021 Q2	$1.32M	Sell	301,904 -13,437	-4%	-$59.6K	0.53%	36
2021 Q1	$1.43M	Sell	315,341 -14,659	-4%	-$78.9K	0.52%	40
2020 Q4	$1.89M	Sell	330,000 -435,000	-57%	-$3.29M	0.52%	38
2020 Q3	$5.54M	Buy	+765,000	New	+$4.09M	1.5%	24
2019 Q2	–	Sell	-517,500	Closed	-$6.87M	–	39
2019 Q1	$6.87M	Buy	+517,500	New	+$5.5M	3.27%	11

Other funds holding CBAY

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Acuta Capital Partners's CBAY Position: Q1 2024 in Review

Acuta Capital Partners sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 492,155 shares — an estimated $11.6M sold.

Acuta Capital Partners first reported a position in CBAY in Q1 2019 and held it in 11 quarters. The position peaked at $11.6M in Q4 2023. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.

Acuta Capital Partners reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
Acuta Capital Partners sold 492,155 Cymabay Therapeutics shares in Q1 2024, an estimated $11.6M.
Acuta Capital Partners first reported a position in Cymabay Therapeutics in Q1 2019 and held it in 11 quarters.
Acuta Capital Partners's Cymabay Therapeutics position peaked at $11.6M in Q4 2023.
1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.

Based on Acuta Capital Partners's 13F filing for Q1 2024, filed 15 May 2024.